ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

Therapeutic Hypothermia After Cardiac Arrest

John McPherson

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

HFpEF in Women

Scripps Health

B. Borlaug

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

TCT 2024 Insights: Insights from the DanGer Shock and ECLS-Shock Tri…

TCT 2024 Insights

G. Tarantini

Cardiotoxicity: Anthracyclines

Scripps Health

M. Davis

Hemodynamic vs. Hemo-Metabolic Shock: Redefining Shock Profiles

The Cardiogenic Shock Working Group

N. Kapur

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Contemporary Management of Cardiogenic Shock: Updates in 2022

Mount Sinai Advanced Innovations in Heart Failure

D. Baran

HFrEF: Essentials of Guideline Directed Medical Therapy Initiation a…

Cleveland Clinic Heart, Vascular and Thoracic Institute

A. Vest

The Valve Trials Are Done: Interventional HFpEF Is the Next Big Thing

Northwestern Medicine Bluhm Cardiovascular Institute

S. Shah

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin